Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival
C. Ling, Celso Pouget, F. Rech, Robin Pflaum, M. Treffel, F. Bielle, K. Mokhtari, Jean-Matthieu Casse, J. Vignaud, M. Kalamarides, M. Peyre, G. Gauchotte
{"title":"Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival","authors":"C. Ling, Celso Pouget, F. Rech, Robin Pflaum, M. Treffel, F. Bielle, K. Mokhtari, Jean-Matthieu Casse, J. Vignaud, M. Kalamarides, M. Peyre, G. Gauchotte","doi":"10.1093/jnen/nlw095","DOIUrl":null,"url":null,"abstract":"Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p = 0.0004, and p = 0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p = 0.017, p = 0.021, and p = 0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p = 0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.","PeriodicalId":16434,"journal":{"name":"Journal of Neuropathology & Experimental Neurology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuropathology & Experimental Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jnen/nlw095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17
Abstract
Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p = 0.0004, and p = 0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p = 0.017, p = 0.021, and p = 0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p = 0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.
微血管增生(MVP)是胶质母细胞瘤的标志。内皮细胞肥大(ECH),也称为内皮增生,与胶质瘤患者较短的生存期相关。然而,这两种形态学特征在脑膜瘤中的预后价值尚未得到研究。本研究的目的是评估脑膜瘤中血管生成的预后价值,尤其是ECH、MVP和微血管密度,在139例脑膜瘤中使用针对CD34和CD105(新生血管标志物)的抗体进行免疫组织化学评估。ECH、MVP和CD105免疫反应性与较高的组织学分级显著相关(p < 0.0001, p = 0.0004, p = 0.0003)。ECH和MVP免疫反应与较短的无进展生存时间(PFS)显著相关(p = 0.017, p = 0.021, p = 0.137),而CD105免疫反应与PFS无关(p = 0.021, p = 0.137)。在Cox多变量分析中,ECH是较短PFS的独立预测因子(p = 0.028)。因此,ECH和MVP是脑膜瘤PFS较短的标志,并与分级显著相关。这些发现为抗血管生成疗法的使用提供了见解。需要进一步的研究来确定这些标记物是否可以让我们识别可以从抗血管生成治疗中获益的患者。